33.42↑-0.07 (-0.21%)
04:01 PM,30th Nov 2023BSE : 511509
NSE :
Sector : Health care
ISIN Code : INE380K01017
Last Updated: Nov 30 2023 | 04:01 PM IST
Market Cap (₹ Cr) | 0 |
Turnover (₹ Cr) | 0.00 |
Volume (Shares) | |
Face Value | 10 |
52-WK High | 0.00 |
52-WK High Date | Invalid date |
52-WK Low | 0.00 |
52-WK Low Date | Invalid date |
All Time High | 0.00 |
All Time High Date | Invalid date |
All Time Low | 0.00 |
All Time Low Date | Invalid date |
Vivo Bio Tech is a full service CRO offering drug development & discovery services to pharmaceutical & biotech companies world-wide in accordance with OECD AAALAC & IND guidelines. The company offers services in the areas of In vitro In vivo toxicity studies pharmacological investigations pharmacokinetics & toxicokinetic studies etc. Our experienced & talented scientists offer advice on defining drug development paths tailored to specific molecules. Tailored and dedicated to our clients we distinguish your development plan is as superlative as the products you bring to our testing facilities.The Biologic Research Services group at Vivo Bio Tech offers a complete line of protein services including gene synthesis cloning expression and purification of recombinant proteins and monoclonal antibodies. Our scientists will team up with you to develop solution for the most difficult to deal products including purification of untagged & poorly expressed proteins.In-vitro Services offers solutions for pharmacologic toxicological & bioanalytical investigations in drug discovery & development. Critical investigations like bacterial reverse mutation assays chromosomal aberration and micronucleus are specialty services by our scientists.The In-vivo Services group at Vivo Bio Tech provides both non-regulatory and regulatory IND enabling preclinical development services. We are capable of screening & evaluating molecules for various pharmacological & therapeutic properties. Specifically for oncology our scientists can provide design & development of xenograft models for evaluation of anti-cancer agents. Further our scientists can customize in-vivo DMPK studies to help profile your drug candidate in both rodent and non-rodent animal models.Vivo Bio has partnered with Taconic for sourcing foundation and expansion colonies of the animal models and have started in-house breeding of Specific Pathogen Free rodents.
PARAMETER | VALUES |
---|---|
Market Cap (₹ Cr) | 49 |
EPS - TTM (₹) [S] | 1.81 |
P/E Ratio (X) [S] | 0.95 |
Face Value (₹) | 10 |
Latest Dividend (%) | - |
Latest Dividend Date | - |
Dividend Yield (%) | - |
Book Value Share (₹) [S] | 35.14 |
P/B Ratio (₹) [S] | 0.95 |
[*C] Consolidated [*S] Standalone |
Scheme Name ↑↓ | Amount Invested ( ₹ Cr ) ↑↓ | No Of Shares ↑↓ | Net Asset (%) ↑↓ |
---|
Date↑↓ | Broker↑↓ | Action↑↓ | Prices(Rs)↑↓ | Report |
---|---|---|---|---|
Data Not Found |
Today's Low/High | 33.00 33.90 |
Week Low/High | 32.50 34.00 |
Month Low/High | 32.00 37.00 |
Year Low/High | 18.11 39.00 |
All time Low/High | 1.05 115.00 |
Period | BSE | NSE | SENSEX | NIFTY |
---|---|---|---|---|
1 Week | 1.46% | % | 1.47 | 1.67% |
1 Month | -1.21% | % | 4.49 | 5.18% |
3 Month | 19.19% | % | 2.92 | 4.06% |
6 Month | 45.43% | % | 6.38 | 8.05% |
1 Year | -3.55% | % | 6.16 | 7.33% |
3 Year | -29.42% | % | 51.73 | 55.24% |
Whole-time Director : Kalyan Ram Mangipudi
Whole-time Director : Alangudi Sankaranarayanan
Chairman & Independent Directo : K Sunder
Independent Director : Hariharan Ravindran
Independent Director : Kunda Kalpana
Director : Karopadi Shivanand Nayak
Whole Time Director & CFO : K Sri Kalyan
Additional Director : Shyam Sunder Tipparaju
Registered Office: Survey #349/A Pregnapur Vlge, ,Gajel,Telangana-502311 Ph:
Email:investors@vivobio.com